[HTML][HTML] Cortical inhibition in neurofibromatosis type 1 is modulated by lovastatin, as demonstrated by a randomized, triple-blind, placebo-controlled clinical trial
Abstract Neurofibromatosis type 1 (NF1) is associated with GABAergic dysfunction which
has been suggested as the underlying cause of cognitive impairments. Previous intervention …
has been suggested as the underlying cause of cognitive impairments. Previous intervention …
Cortical inhibition in neurofibromatosis type 1 is modulated by lovastatin, as demonstrated by a randomized, triple-blind, placebo-controlled clinical trial.
I Bernardino, A Dionísio… - Scientific Reports, 2022 - search.ebscohost.com
Abstract Neurofibromatosis type 1 (NF1) is associated with GABAergic dysfunction which
has been suggested as the underlying cause of cognitive impairments. Previous intervention …
has been suggested as the underlying cause of cognitive impairments. Previous intervention …
Cortical inhibition in neurofibromatosis type 1 is modulated by lovastatin, as demonstrated by a randomized, triple-blind, placebo-controlled clinical trial
I Bernardino, A Dionísio, M Castelo-Branco - 2022 - pubmed.ncbi.nlm.nih.gov
Neurofibromatosis type 1 (NF1) is associated with GABAergic dysfunction which has been
suggested as the underlying cause of cognitive impairments. Previous intervention trials …
suggested as the underlying cause of cognitive impairments. Previous intervention trials …
Cortical inhibition in neurofibromatosis type 1 is modulated by lovastatin, as demonstrated by a randomized, triple-blind, placebo-controlled clinical trial
I Bernardino, A Dionísio… - Scientific Reports, 2022 - ui.adsabs.harvard.edu
Abstract Neurofibromatosis type 1 (NF1) is associated with GABAergic dysfunction which
has been suggested as the underlying cause of cognitive impairments. Previous intervention …
has been suggested as the underlying cause of cognitive impairments. Previous intervention …
Cortical inhibition in neurofibromatosis type 1 is modulated by lovastatin, as demonstrated by a randomized, triple-blind, placebo-controlled clinical trial
I Bernardino, A Dionísio, M Castelo Branco - Nature, 2022 - estudogeral.uc.pt
Neurofibromatosis type 1 (NF1) is associated with GABAergic dysfunction which has been
suggested as the underlying cause of cognitive impairments. Previous intervention trials …
suggested as the underlying cause of cognitive impairments. Previous intervention trials …
[HTML][HTML] Cortical inhibition in neurofibromatosis type 1 is modulated by lovastatin, as demonstrated by a randomized, triple-blind, placebo-controlled clinical trial
I Bernardino, A Dionísio, M Castelo-Branco - Scientific Reports, 2022 - ncbi.nlm.nih.gov
Abstract Neurofibromatosis type 1 (NF1) is associated with GABAergic dysfunction which
has been suggested as the underlying cause of cognitive impairments. Previous intervention …
has been suggested as the underlying cause of cognitive impairments. Previous intervention …
Cortical inhibition in neurofibromatosis type 1 is modulated by lovastatin, as demonstrated by a randomized, triple-blind, placebo-controlled clinical trial.
I Bernardino, A Dionísio, M Castelo-Branco - Scientific Reports, 2022 - europepmc.org
Abstract Neurofibromatosis type 1 (NF1) is associated with GABAergic dysfunction which
has been suggested as the underlying cause of cognitive impairments. Previous intervention …
has been suggested as the underlying cause of cognitive impairments. Previous intervention …